FDA

The Food and Drug Administration (FDA) is a United States federal regulatory agency within the Department of Health and Human Services. It determines whether a drug may be marketed in the United States, for which conditions, and under what restrictions. Its authority derives from the Federal Food, Drug, and Cosmetic Act.

FDA authority is distinct from scheduling authority, which belongs to the Drug Enforcement Administration under the Controlled Substances Act. Approval by one agency neither requires nor implies action by the other: a substance can carry FDA authorisation while remaining in the most restrictive DEA schedule, or be available internationally without the manufacturer ever having sought FDA review.

What it means in practice

Before a drug may be sold commercially in the United States, its manufacturer must submit a New Drug Application demonstrating safety and efficacy through clinical trials. During development, investigational use in humans proceeds under an Investigational New Drug application, which permits trials to begin before any approval is granted.

The FDA also confers expedited designations — Breakthrough Therapy, Fast Track, Priority Review, and Accelerated Approval among them — to compounds showing early promise against serious conditions. These change the pace and structure of the review process; they do not constitute approval. A compound can receive a Breakthrough Therapy designation and later be declined for market authorisation.

Approval is indication-specific. A drug authorised for one condition is not automatically authorised for others, though physicians may prescribe it off-label once it reaches the market.

How jurisdictions vary

FDA approval applies only within the United States. Equivalent agencies operate independently elsewhere: the European Medicines Agency governs the European Union; the Medicines and Healthcare products Regulatory Agency covers Great Britain; Health Canada and the Therapeutic Goods Administration serve Canada and Australia respectively.

These agencies share data and sometimes coordinate reviews, but approval in one jurisdiction does not transfer to another. A compound approved in several countries may have no FDA authorisation, and vice versa. DEA scheduling status travels on a separate track still: a substance's standing with overseas regulators has no bearing on which schedule it occupies under the Controlled Substances Act.

What is contested

The FDA and DEA operate under different statutory tests, and their determinations can diverge publicly. The Controlled Substances Act places substances in Schedule I partly on the finding of no currently accepted medical use — a legal phrase the DEA applies, not a scientific determination the FDA makes. The FDA can grant a Breakthrough Therapy designation to a Schedule I compound, signalling that clinical evidence is promising enough to expedite review, while the compound retains its scheduling status until a separate DEA proceeding acts on it.

A concrete example: the FDA authorised a cannabidiol formulation for specific epilepsy indications while cannabis remained Schedule I at the federal level. The statutory phrase and the regulatory record ran on separate tracks, neither automatically updating the other.

Scope and currency

This entry describes the FDA's general authority and functions; it is not legal advice and does not describe the regulatory or scheduling status of any specific substance in any jurisdiction. Entry positions are stated as of August 2026. For the current approval and legal status of a specific compound, consult the Legal Status section on its substance page, which carries its own jurisdiction, date, and cited source.